Article
Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment.
Diagnostic pathology - 30 Jan 2020
Krieger Tina, Pearson Isobel, Bell Judith, Doherty Jim, Robbins Paul
Abstract excerpt
BACKGROUND: To achieve optimal outcomes, an individual approach is needed in the treatment and care of patients. The potential value of tumor mutational burden (TMB) status and/or programmed cell death ligand 1 (PD-L1) expression as biomarkers to predict which patients are most likely to respond to checkpoint inhibitors has been explored in many studies. The goal of this targeted literature review is to identify...
Topics
- Apoptosis
- B7-H1 Antigen
- Biomarkers, Tumor
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Gene Expression Profiling
- Humans
- Kidney Neoplasms
- Lung Neoplasms
- Lymphocytes, Tumor-Infiltrating